Exocrine Pancreatic Insufficiency Market Report 2026

The exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.75 billion in 2025 to $2.93 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to rising prevalence of chronic pancreatitis, increasing awareness of digestive disorders, improved availability of enzyme therapies, expansion of hospital pharmacy networks, growth in diagnostic testing adoption.

The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to advancements in enzyme formulation technologies, rising geriatric population, increasing demand for homecare treatment, growth of online pharmacies, improved reimbursement for digestive disorder treatments. Major trends in the forecast period include increased adoption of pancreatic enzyme replacement therapy, rising focus on early and accurate diagnosis, growth in home-based nutritional management, expansion of online pharmacy distribution, improved patient awareness and education programs.

The rising prevalence of chronic diseases is expected to drive the growth of the exocrine pancreatic insufficiency (EPI) market going forward. Chronic diseases are long-term medical conditions that typically persist for three months or more. The prolonged presence of these underlying conditions can increase the risk of developing secondary complications such as exocrine pancreatic insufficiency, emphasizing the need for effective medical interventions and therapies to manage chronic conditions and improve patient longevity. For instance, in September 2023, the World Health Organization, a UN specialized agency based in Switzerland, reported that 41 million deaths occur annually, with 74% attributed to non-communicable diseases (NCDs) or chronic conditions worldwide. Therefore, the rise in chronic diseases is driving the growth of the exocrine pancreatic insufficiency market.

Major companies in the exocrine pancreatic insufficiency market are focusing on establishing patient advocacy initiatives, such as comprehensive nutritional guidance programs, to support and educate affected individuals. These programs aim to improve awareness, provide tailored dietary recommendations based on individual needs, health conditions, and lifestyles, and promote overall well-being. For instance, in June 2024, Nestlé Health Science, a Switzerland-based nutrition company, launched a GLP-1 nutrition support platform. The platform offers personalized nutritional resources and expert guidance for individuals using GLP-1 medications, focusing on muscle preservation, gut health, and general wellness, while fostering community support and empowering users in their weight management journey.

In December 2023, Codexis, a US-based pharmaceutical company, acquired a Nestlé Health Science company for an undisclosed amount. Through this acquisition, Codexis aims to monetize its asset CDX-7108, focus on core projects, and leverage Nestlé’s expertise to accelerate development while retaining economic interest. Nestlé Health Science, a Switzerland-based science-focused nutrition company, provides specialized nutritional products designed to support individuals with exocrine pancreatic insufficiency by improving digestion and nutrient absorption.

Major companies operating in the exocrine pancreatic insufficiency market are Nestlé Health Science S.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Enzymedica Inc., Alcresta Therapeutics Inc., Chiesi Farmaceutici S.p.A., Amryt Pharma Plc, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Eli Lilly and Company, Medtronic plc, First Wave BioPharma Inc., Vivus Inc., Abbott Laboratories, Danone S.A., Fresenius SE & Co. KGaA, Baxter International Inc, Siemens Healthineers AG, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc, Koninklijke Philips N.V., Fujifilm Holdings Corporation.

North America was the largest region in the exocrine pancreatic insufficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the exocrine pancreatic insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the exocrine pancreatic insufficiency market by increasing costs of imported pancreatic enzyme formulations, diagnostic reagents, and imaging equipment. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported enzyme therapies. These tariffs raise overall treatment costs. However, they support domestic enzyme manufacturing and strengthen regional pharmaceutical supply chains.

The exocrine pancreatic insufficiency market research report is one of a series of new reports that provides exocrine pancreatic insufficiency market statistics, including exocrine pancreatic insufficiency industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency market share, detailed exocrine pancreatic insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the exocrine pancreatic insufficiency industry. This exocrine pancreatic insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the pancreas's insufficient production or release of digestive enzymes into the small intestine. These enzymes are essential for the digestion and absorption of nutrients from food. Exocrine pancreatic insufficiency can lead to malnutrition and digestive symptoms, including diarrhea, abdominal pain, bloating, and weight loss.

The main types of exocrine pancreatic insufficiency treatments are nutritional management, pancreatic enzyme replacement therapy (PERT), and others. Nutritional management refers to the practice of planning and implementing dietary strategies to optimize an individual's nutritional status and support their overall health and well-being, and it also plays a crucial role in the comprehensive care of individuals with exocrine pancreatic insufficiency (EPI), diagnosed with imaging tests such as Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), and others to identify symptoms such as abdominal pain, constipation, diarrhea, fatty stool, weight loss, and others. The drugs are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other channels that are used in the treatment of exocrine pancreatic insufficiency by end users, including hospitals, specialty clinics, and homecare.

The exocrine pancreatic insufficiency market consists of revenues earned by entities by providing enzyme replacement therapy, nutritional counseling, monitoring, managing underlying conditions, lifestyle modifications, and gastroenterology consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency market also includes sales of Creon, zenpep, pancreaze, ultresa, and viokace. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.